Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

MTX325

Source date not recordedAnalyse record ↗

Investigational USP30 inhibitor designed to enhance clearance of dysfunctional mitochondria through mitophagy in Parkinson's disease.

Modality
brain-penetrant small-molecule USP30 inhibitor
Availability (US)
Phase 1 clinical development
Biomarkers
USP30 inhibition; mitophagy target engagement; pharmacokinetics; brain penetration
Hallmark targeted
mitochondrial dysfunction, mitophagy, proteostasis
Kind
investigational drug
Other papers
Fang et al., Nature Communications 2023; DOI 10.1038/s41467-023-42876-1
Clinical trials
ISRCTN20898392; Phase 1 study in healthy volunteers and people with Parkinson's disease